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ABSTRACT
Background: Malaria in pregnancy is associated with many negative outcomes for the woman, 
foetus and neonate. Intermittent preventive treatment during pregnancy (IPTp) using three doses 
of sulfadoxine/pyrimethamine (SP), insecticide-treated mosquito nets (ITNs) and indoor residual 
spray (IRS), constitute the main strategies used to prevent malaria. The aim of this study is to 
evaluate the effectiveness of these strategies for the reduction of malaria prevalence in pregnant 
women.
Methods: A questionnaire on socio-demographic information, history of malaria during current 
pregnancy and prevention strategies used was administered to 450 consecutive patients admitted 
into labour wards at three local clinics. From the antenatal cards, information was collected on the 
last menstrual period, date of each dose of SP taken, gravidity, and HIV status. A blood slide to 
detect Plasmodium was then collected from each woman after consent.
Results: Of the participants in the study, 2.4% had a positive blood slide at term and 15.8% reported 
malaria during pregnancy. All the participants took at least one dose of SP with 87.6% completing 
the stipulated three doses. The mean gestational ages for each dose were 22.1 (SD 4.6), 29.1 (SD 4.4) 
and 34.4 (SD 3.9) weeks for the first, second and third dose respectively. With regard to ITNs, 79.5% 
had one, but only 74.1% used it regularly. IRS was completed in all three of the clinics’ catchment 
areas. Only 23.4% used commercial insecticide.
Conclusion: The measured prevalence of malaria at term in Ndola was remarkably low, although 
the self-reported rate during pregnancy was still high. The national targets for accessing IPTp were 
exceeded, although the timing of each dose needs to be improved. Access to ITNs was high, but 
usage needs to increase. 
INTRODUCTION
Malaria infection due to Plasmodium falciparum still causes significant morbidity and mortality in countries 
with limited resources that are situated in endemic zones. It is still a global health problem, with most of 
the disease burden carried by children younger than 5 years of age and pregnant women.1 It is estimated 
that up to 90% of global cases of malaria occur in sub-Saharan Africa.1,2
Although there are four species causing malaria, most complications are due to the P. falciparum species.1,2,3 
In pregnancy, malaria poses a risk to the mother, the foetus and the neonate. In areas of stable malaria 
where adult women have considerable acquired immunity, P. falciparum infection during pregnancy 
does not typically develop into a symptomatic febrile disease, but rather leads to maternal anaemia and 
placental malaria infection, particularly in the primigravidae and the secundigravidae.1,2,3,4 On the other 
hand, pregnant women who are HIV-positive are particularly vulnerable to malaria.5,6,7,8 P. falciparum 
is associated with an increased risk of maternal anaemia and mortality. It is also accompanied by an 
increased risk of prematurity. 
Placental malaria can lead to cord anaemia, intrauterine growth retardation, low birth weight (LBW), 
and possibly intrauterine death. Neonatal malaria is also possible and leads to an increased risk of infant 
mortality.1,9,10
All of these complications can be avoided by cost-effective prevention of malaria in pregnancy, as well as 
early detection and effective treatment of patients.
Zambia is a southern African country where malaria is endemic and still constitutes a major public 
health problem. The Zambian government has designated malaria control as one of its priorities, as 
demonstrated in the National Health Strategic Plan 2006−2010.11 It is estimated that in Zambia, 3.4 million 
cases of malaria occur every year, translating into 308 infections per 1000 persons each year and that 
sulfadoxine/pyrimethamine (SP) total treatment failure has risen from 14.5% in 2003 to 37.0% in 2004.5 
The HIV prevalence in Zambia is 16.0% amongst adults aged 15−49 years, while amongst pregnant 
women attending antenatal care, the prevalence is 19.0%.12
Currently, efforts to control malaria in Zambia are being escalated and coordinated under the Roll Back 
Malaria (RBM) initiative. Under this initiative, the Zambian government, in collaboration with other 
partners, has come up with four strategies, namely (1) use of insecticide-treated mosquito nets (ITNs), (2) 
indoor residual spray (IRS) in all houses, with pyrethroids and dichlorodiphenyltrichloroethane (DDT), 
(3) use of intermittent preventive treatment of malaria in pregnancy (IPTp) and (4) prompt, effective case 
management.
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 IPTp was introduced in 2003 and requires three doses of an SP 
combination that are given to pregnant women at the gestational 
ages of 16, 20 and 24 weeks during their antenatal care visits.13 
Though studies elsewhere advise monthly SP for HIV-positive 
pregnant women,14,15 a 2007 Zambian study concluded that in 
zones of meso-endemic malaria transmission, this was not more 
efficacious than the standard regimen.5
The use of SP in pregnancy as IPTp has been demonstrated to be 
safe, however, its concomitant use with co-trimoxazole or with 
high-dose folic acid is not advisable.16 The implication of this 
is crucial for HIV-positive women who are on co-trimoxazole 
prophylaxis.
At the antenatal visits, ITNs are also distributed at a very 
subsidised price of $1.00 per net and health talks about the 
effects of malaria on pregnancy are communicated. IRS spraying 
at home is provided through the District Health Management 
Team (DHMT).
The Ministry of Health recommends that pregnant women 
diagnosed with malaria be treated with quinine only in the 
first trimester, or if the malaria is severe. In the second and 
third trimesters, SP should be prescribed. The treatment should 
commence within 24 hours of the onset of symptoms.11,13
Although the Zambian malaria control programme in pregnant 
women was implemented in 2003, its success has not been widely 
studied. The aim of this study was to evaluate the effectiveness 
of strategies employed to prevent malaria in pregnant women 
in Ndola, Zambia and, if possible, to make recommendations on 
how prevention can be improved.
The specific objectives were:
•	 To determine the proportion of pregnant women who have 
access to and complete the recommended three-dose course 
of IPTp.
•	 To determine the gestational age at which each dose of IPTp 
is taken. 
•	 To determine the prevalence of maternal parasitemia at term 
in pregnant women taking SP/IPTp.
•	 To determine the proportion of pregnant women who sleep 
under ITNs regularly.
•	 To describe the provision of IRS and other non-official 
strategies used by pregnant women to prevent malaria.
•	 To determine what type of medication is prescribed to 
pregnant women when they contract malaria.
ETHICAL CONSIDERATIONS
The study was approved by the Human Research Ethics 
Committee, Stellenbosch University, South Africa and the Ethics 
Committee, Tropical Disease Research Centre, Zambia. 
METHODS
A cross-sectional study evaluated the effect of the RBM 
prevention strategy on the prevalence of malaria in pregnancy 
within the maternity ward. 
Settings
The study was conducted in three health clinics in the suburb 
of Ndola between January and April 2009. Ndola is one of the 
urban centres in the Copperbelt province of Zambia, in southern 
Africa. These three clinics provide health care to approximately 
96 000 people. In all three clinics women give birth routinely 
and the strategies for malaria prevention in pregnancy follow 
the national programme. This includes sleeping under an ITNs, 
receiving three doses of SP and yearly IRS with pyrethroids and 
dichlorodiphenyltrichloroethane (DDT), which is carried out by 
the Ndola DHMT.
Every woman attending antenatal classes is educated on HIV 
and prevention of mother-to-child transmission. Zambia uses 
the opt-out strategy when it comes to HIV testing in pregnant 
women. The HIV status is then coded on the antenatal card and 
on the under-5 card of the child after birth.
Sample size
Taking into consideration that in the chosen three clinics, the 
total average number of deliveries is 7000 per annum and the 
expected malaria prevalence at delivery is 13.6% without IPTp 
and 6.3% after IPTp.17 For the purpose of the study a minimum 
sample size of 350 was calculated using Cochrane’s cross-section 
survey sample size calculation.
Enrolment
Participants who had given informed consent and were at 
least 28 weeks pregnant and 18 years or older, were enrolled 
consecutively as they came into the maternity ward. We excluded 
those with (1) a history of splenectomy, (2) sickle cell disease, (3) 
allergy to sulfadoxine/pyrimethamine and (4) those that came 
to the maternity ward without the antenatal cards. Enrolment 
into the study ceased once 450 patients had consented.
Questionnaire procedures
The purpose of the study and its requirements were explained 
to the patients prior to obtaining written, informed consent from 
each participant. Enrolled women were given a questionnaire by 
the local midwife to collect (1) socio-demographic information, 
(2) history of malaria during the current pregnancy, (3) any 
anti-malarial treatment and (4) malaria prevention strategies 
used. From each participant’s antenatal card, information was 
collected (1) on the last menstrual period, (2) date at which each 
dose of IPTp was taken, (3) gravidity and (4) HIV status. 
Laboratory procedures
A drop of blood was collected using a fingerprick sample, and a 
blood slide was prepared and air-dried. The slides were stained 
with Giemsa stain and then examined at the Tropical Disease 
Research Centre twice a week by a laboratory technician. The 
number of parasites per 200 white blood cells determined the 
parasite count and a slide was only considered negative after 
100 oil-immersion fields were examined and no parasite found 
to be present.
RESULTS
Out of the 450 participants (150 from each clinic), 11 (2.4%) blood 
slides tested positive for malaria parasite and 439 (97.6%) tested 
negative. Their characteristics are shown in Table 1. 
Information about the gravidity of five participants was absent. 
Of the 445 for whom gravidity information was available, 122 
(27.4%) were either primigravidae or secundigravidae. This 
represents the group of pregnant women who are at a higher 
risk for adverse outcomes.
Out of the 445 participants who revealed their HIV status, 89 
(20.0%) were HIV-positive. Of these, 15 (16.9%) were either 
primigravidae or secundigravidae. This means that 15 women 
out of the 445 were both HIV-positive and either primigravidae 
or secundigravidae, representing 3.4%.
Of the 450 participants, all had taken at least one dose of SP 
(100.0%), and 394 (87.6%) had completed the course of all three 
doses. Overall, 99.1% of participants took two or three doses of 
IPTp.
The mean gestational ages for each dose were 22.1 (SD 4.6), 29.1 
(SD 4.4) and 34.4 (SD 3.9) weeks for the first, second and third 
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doses respectively. Only 18 participants (4.1%) took the first 
dose at 16 weeks, 3 (0.7%) took the second dose at 20 weeks and 
1 (0.3%) took the third dose at 24 weeks, as recommended in 
the national guidelines. In addition, 14.9% of the women who 
took three doses of IPTp received their last dose after 38 weeks 
of gestation.
We found that 448 participants owned ITNs; of these, only 
356 (79.5%) actually used them. The results also show that 332 
women (73.8%) used their ITNs regularly (four times a week or 
more).
Information collected about the use of commercial insecticide 
showed that 105 respondents (23.4%) had used it. Only 35 (7.8%) 
used it regularly; this means that the majority of our participants 
(92.3%) either used it occasionally, or not at all. More importantly, 
76 (72.4%) women out of the 105 still used ITNs regularly. Only 
five participants (1.1%) applied any mosquito repellents.
Although only 2.4% of women were positive for malaria when 
tested (Table 1), 15.8% reported that they had malaria during 
their pregnancy and received treatment, as shown in Table 2. 
Almost two-thirds of women who suffered from malaria were 
treated with SP, while only a third (36.6%) received quinine. 
Out of the 11 women who had a positive slide, 5 were HIV-
positive, representing 45.5% of the positive slides. Of the 89 
HIV-positive participants, these 5 suggest a prevalence of 5.6%, 
which is more than double the baseline value. 
The DHMT confirmed that IRS spraying had been performed 
throughout the catchment areas of all three clinics during the 
previous year.
DISCUSSION
Main findings of this study
Overall, the RBM programme was implemented effectively, 
with 87.6% of pregnant women receiving three doses of SP, 
79.5% owning an ITNs and households in all areas being offered 
IRS. The timing of the three doses of SP was not aligned with 
the guidelines and only 74.1% used their ITNs regularly. Only 
a small number of women supplemented the official strategies 
with the use of their own commercial insecticides and repellents. 
The prevalence of malaria in the maternity ward was low at 
2.4%, whilst the self-reported prevalence during pregnancy was 
15.8%.
Comparison to previous studies
The prevalence of malaria in this study is significantly lower 
than the 6.3% found in Mozambique (with two doses of SP as 
the prevention strategy).17 The difference can be explained by 
the fact that in the Zambian situation, many other strategies are 
simultaneously implemented, such as IRS and ITNs, as part of 
the Integrated Vector Control Programme, in conjunction with 
the prompt treatment of infected individuals. 
Although it was found that 15.8% of participants reported 
having suffered from malaria during their current pregnancy, 
many people suffering from any febrile illness in an endemic 
region like Zambia would call it malaria and a large number 
will self-medicate.18 In addition, most pregnant women who 
present at their local clinic with fever are likely to be told that 
they are suffering from malaria and receive treatment with anti-
malarial medication. Many health care workers still prescribe 
TABLE 2
Self-reported malaria and treatment received
Variable n %
Malaria
no 377 84.2
yes 71 15.8
Total 448 -
Curative medication received
artemisinin 1 1.4
SP† 44 62
quinine 26 36.6
Total 71 -
†SP, sulfadoxine/pyrimethamine.
3
TABLE 1
Characteristics of enrolled women participants
Characteristics n %
Marital status
single 20 4.4
married 430 95.6
Total 450 -
Gravidity
primigravidae and secundigravidae 122 27.4
multigravidae (three or more) 323 72.6
Total 445 -
Education level
primary school (Grades 1−7) 153 34.5
secondary school (Grades 8−12) 281 63.4
tertiary school (college or university) 9 2.0
Total 443 -
HIV status
positive 89 20.0
negative 356 80.0
Total 445 -
IPT†
no 0 0.0
yes (any dose) 450 100.0
one dose 4 0.9
two doses 52 11.6
three doses 394 87.6
Total 450 -
ITN use†
no 92 20.5
yes 356 79.5
regularly (four or more times per week) 332 93.3
occasionally (twice or three times per week) 16 4.5
seldom (once or less per week) 8 2.2
Total 448 -
Commercial insecticide use
no 343 76.6
yes 105 23.4
regularly (four or more times per week) 35 33.3
occasionally (twice or three times per week) 33 31.4
seldom (once or less per week) 37 35.2
Total 448 -
Repellents use
no 443 98.9
yes 5 1.1
regularly (four or more times per week) 0 0.0
occasionally (twice or three times per week) 3 60.0
seldom (once or less per week) 2 40.0
Total 448 -
Blood slide results
positive 11 2.4
negative 439 97.6
Total 450 -
†IPT = intermittent preventive treatment; ITN = insecticide-treated mosquito net.
n = given as means of value.
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anti-malarial treatment, even when the malaria test is negative.18 
Nonetheless, this percentage is similar to the 15.7% malaria 
parasitemia found in Burkina Faso.4 In this case, the study 
was done in a more rural area, the prevention strategy did not 
include regular IRS, and the IPTp progamme had only been 
running for 1 year. On the other hand, the fact that malaria in 
pregnancy is usually asymptomatic means that many pregnant 
women with no fever do not seek medical advice, even if they 
may have malaria. The true prevalence of malaria in pregnancy, 
therefore, can only be fully assessed through placental biopsy.
Although the levels of total treatment resistance to SP have 
increased over the past few years, its effectiveness as an 
intermittent preventive treatment is still high.14 It is also 
possible that the use of IPTp as an integrated part of a larger 
strategy including other measures, such as ITNs, increases the 
effectiveness.
The Zambian Ministry of Health (MoH) and the World Health 
Organization (WHO) recommend quinine as the drug of choice 
during the first trimester and in severe malaria in pregnancy, 
while SP can be prescribed in the second and third trimesters.1,13 
However, with the current SP resistance level in Zambia,19 
cost-effectiveness studies should be conducted with a view to 
prescribing quinine throughout pregnancy. The WHO actually 
recommends that in areas of combined resistance to chloroquine 
and SP, quinine should be the first-line drug, even in second 
and third trimester.1 In addition, studies should be done, 
locally, to assess the possible use of artemisinin and artemisinin 
combination therapies (ACT). Currently, Zambia does not 
recommend prescription of ACT during pregnancy, as there 
is no evidence base to show its safety. There is emerging data 
showing that artesunate and ACT are safe and efficacious in 
pregnancy.20 Further studies are required to evaluate alternatives 
to SP in the light of increasing resistance.
The use of IPTp met the goal of the Zambian MoH to ensure 
access to IPTp for at least 80% of women by December 2008. 
The level exceeds the findings of the Zambia National Malaria 
Survey in 2006, which recorded that 85.9% of urban women 
accessed any IPTp and only 71.2% took all three recommended 
doses.
On average, the first dose was received 6 weeks later than 
recommended; the second dose was 7 weeks after the first, and the 
third dose 5 weeks after the second; instead of the recommended 
4-week interval. This late delivery certainly increases the time 
that pregnant women spend at risk. In addition, there are 
suggestions that the late delivery of the first dose of IPTp could 
be related to the subsequent late delivery of the other following 
doses, or lead to an incomplete IPTp schedule.21 Infection in 
early or late pregnancy has been associated with more negative 
effects on the pregnancy outcome22 and this fact should be the 
basis for advocating that the first dose of IPTp be on time.
The use of ITNs is not far below the target of 80% of pregnant 
women accessing ITNs by December 2008, as stated in the 
National Health Strategic Plan 2006−2010.11 Though the 
document is silent about the target concerning the use of these 
nets, we would want to believe that the intention of the document 
was to achieve a comparable target. This means that the current 
usage rate (74.1%) is well below the expected rate. Nonetheless, 
there has been tremendous improvement when compared to 
18% of urban women who slept under an ITNs in 2006.23
Application of insect-repellent ointments or lotion is not 
a practice that is commonly embraced by the population. 
However, there is evidence to show that insect repellent in 
addition to ITNs provides greater protection, especially in areas 
where mosquitoes feed in the early evening, and between dusk 
and bedtime.24 In countries with restricted economic power, 
this might not be a cost-effective programme, but one which is 
particularly advocated for tourists and those who can afford it. 
However, more studies are needed to clarify their safety profile 
in pregnancy.
Limitations
The exact prevalence of malaria during the whole of pregnancy 
could not be determined by this cross-sectional study within 
the maternity ward. These women were also likely to have 
frequented the same clinics for their antenatal visits and would 
most likely have been educated about the risk factors related to 
pregnancy in general and malaria in particular. Therefore they 
were more likely to have received IPTp and to use ITNs. The 
results, therefore, for the whole community of pregnant women, 
which includes those giving birth at home, those not attending 
the clinic and those in rural areas, are likely to be worse. The 
number of women refusing to participate in the study was 
not recorded by the research assistants and the uptake of IRS 
per household was not confirmed in the questionnaire. The 
questionnaire could have attempted to verify the gestational age 
of reported malaria and use of diagnostic tests, although this 
would still have been subject to a potential reporting and recall 
bias.
Recommendations
Further studies should attempt to determine the rates of malaria 
throughout pregnancy and to assess if the self-reported rate of 
15.8% is correct. 
There is a need to improve the gestational age at which the first 
dose of IPT is delivered, as well as the follow-up doses. This 
can be achieved through education of health care providers and 
community sensitisation by health talks given during antenatal 
classes.
Although access to ITNs has improved dramatically, attention 
must now be given to the usage rate. There is a need for more 
educational messages to pregnant women about the dangers 
of malaria, the emphasis on taking IPT on time, and always 
sleeping under ITNs, especially if one is HIV-positive. The 
correct treatment of malaria in pregnancy as well as the risks of 
over-prescription of anti-malaria drugs needs to be emphasised 
to health care workers, during continuing medical education 
sessions. More research needs to be conducted to evaluate the 
situation in rural areas and amongst those women who give 
birth at home with the help of traditional birth attendants.
CONCLUSION
The aim of this study was to evaluate the effectiveness of 
strategies employed to prevent malaria in pregnant women 
in Ndola, Zambia, and if possible to make recommendations 
on how prevention can be improved. The study evaluated 
450 consecutive pregnant women admitted into maternity 
wards at three local clinics. Overall, the Rolling Back Malaria 
programme was implemented effectively, with 87.6% of 
pregnant women receiving three doses of SP, 79.5% owning an 
ITNs and households in all areas being offered IRS. The timing 
of the three doses of SP was not aligned with the guidelines and 
only 74.1% used their ITNs regularly. Only a small number of 
women supplemented the official strategies with the use of their 
own commercial insecticides and repellents. The prevalence of 
malaria in the maternity ward was low at 2.4%, whilst the self-
reported prevalence during pregnancy was 15.8%. The results 
show that the programme is on target for use of IPTp, although 
improvements can be made on the timing of SP doses and the 
actual usage of the ITNs.  
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